Shake It Off? Japan Mulls Routes Out Of Bioventure Doldrums
Nurturing, Translational Research Hopes Aired At BioJapan
The long-recurring theme of how effectively to foster Japan’s bioventure sector again emerged as a key thread at recent major industry meeting, while the broader topic of effective partnering occupied the minds of industry and academia alike.
You may also be interested in...
While industry participants at BioJapan expect big pharma to continue to seek external partnerships and acquisitions to bolster pipelines, the technology and countries involved in such alliances look set to change.
Big pharma partner takes on prime development responsibility for novel AMD cell therapy as Japanese venture concentrates resources on other in-progress trials.
CEO of the Stevenage-based center hopes the new cell and gene manufacturing hub will see a growing life sciences ecosystem coalesce around it.